You are here

Assure Holdings Reports First Quarter 2018 Financial Results

– Revenue Increases by 86% to $5.7 Million, Net Income up 30% to $3.0 Million –

– Management to Discuss First Quarter Results via Conference Call on Monday, August 20, 2018, at 11:30 A.M. Eastern Time –

DENVER, Aug. 17, 2018 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services, reported financial results for the three months ended March 31, 2018, and revised results for the three months ended March 31, 2017.

First Quarter 2018 Financial Summary vs. Revised First Quarter 2017

  • Total revenue grew 86% to $5.7 million versus a revised $3.1 million.
  • Managed cases increased 74% to 565 versus 325.
  • Gross margin up 180 basis points to 83.5% versus a revised 81.7%.
  • Earnings from equity method of investment in Physician Network Entities (PNEs) grew 109% to $0.9 million from a revised $0.4 million.
  • Net income increased 30% to $3.0 million compared to a revised net income of $2.3 million. Revised net income in 2017 was not burdened by tax expense as the Company modified its tax provision methodology at the end of 2017.
  • Diluted earnings per share was $0.07 per share compared to a revised $0.08 per share. The 2018 number reflects the full impact of the shares issued in conjunction with the Company’s reverse take-over transaction to become a public company on the TSXV and the performance shares.
  • Adjusted EBITDA grew 80% to $4.2 million versus a revised $2.3 million.

Management Commentary

“During the first quarter, Assure expanded beyond its historical Colorado base, growing significantly in Louisiana and expanding into Utah,” said John A. Farlinger, Assure’s Executive Chairman and Interim CEO. “Case volumes grew in Texas—a market that the Company entered last November. The expansion into these new markets helped drive strong first quarter results, and Assure continued to experience improving case volumes into the second quarter of 2018. We look forward to carrying this momentum in the remainder of the year as we continue to drive the commercial acceptance of our unique neuromonitoring platform.

“Our strong first quarter 2018 results, on the heels of our recent filing of our positive 2017 results, continues to demonstrate broad market adoption and the strong operational performance of our business model.”

First Quarter 2018 Financial Results

Total revenue in 2018 increased 86% to $5.7 million compared to a revised $3.1 million in the first quarter of 2017. The significant improvement was due to increased cases generated from the Company’s existing surgeon network, the onboarding of additional surgeons throughout 2017, and the expansion into new states. In fact, revenue generated outside Colorado was 18% of total revenue in the first quarter of 2018. Managed cases increased 74% to 565 versus 325 in the first quarter of 2017, primarily driven by expansion beyond the Colorado market.

Gross margin increased 180 basis points to 83.5% compared to a revised 81.7% in the same quarter last year as the fundamentals of the business sustained the strong revenue growth.

Total operating expenses increased to $1.7 million compared to $0.6 million in the same quarter in 2017 due to additional sales and marketing investments, onboarding new executives, share-based compensation expense, as well as ongoing corporate expenses in the wake of becoming a public company in the second quarter of 2017.

Net income in 2018 increased to $3.0 million or $0.07 per diluted share, compared to net income of $2.3 million or $0.08 per diluted share in the first quarter of 2017. The 2018 per diluted share amount reflects 17.6 million of incremental diluted shares relating to the Company’s merger with Montreux Capital and subsequent public listing and performance shares.

Adjusted EBITDA increased 80% to $4.2 million compared to $2.3 million in the same quarter in 2017 due to the increase in cases managed, which improved revenue and earnings from the equity method of investment in Assure’s PNEs.

Collected $1.4 million of cash from accounts receivable compared to $1.1 million in the first quarter of 2017. Cash distributions from PNE entities totaled $0.3 million in the three months ended March 31, 2018, compared to $0.027 million in the same prior year period. Total cash inflows from collections and distributions increased 49% year over year, as collections from 2017 growth accelerated.

Assure has also filed its unaudited condensed interim financial statements and management discussion & analysis (MD&A) with SEDAR. This information can be found at

Subsequent Events: Debt Settlement Agreement with Preston Parsons and Resignation of Peter Csapo, CFO

On August 16, 2018, the Company entered into a Release, Pledge and Security Agreement (“the Agreement”) with Preston Parsons. The Agreement provides for a secured promissory note whereby Mr. Parsons agrees to repay the Company $2,086,886 by December 31, 2018. The repayment includes amounts attributed to third-party costs incurred by the Company and imputed interest of 8%. The secured promissory note is secured by a pledge of 5,600,000 common shares of stock held by Mr. Parsons. The Agreement provides for a mutual release.

At the close of business on August 17, 2018, Peter P. Csapo, Chief Financial Officer, tendered his resignation, indicating his plans to join another healthcare company that is not a competitor to Assure. Farlinger commented: “We appreciate Peter staying on to navigate the Company through its recent restatement and becoming current in its filings. During his tenure, he in-sourced our accounting function to a new internal team and we are now appropriately resourced to handle the second quarter filing. It has been a pleasure to work with Peter and we wish him the best in his new undertaking.”

Conference Call

The Company will hold a conference call Monday, August 20, 2018, at 11 30 a.m. Eastern time to discuss its first quarter 2018 results.

Date: Monday, August 20, 2018
Time: 11:30 a.m. Eastern time
Toll-free dial-in number: 1-877-407-0792
International dial-in number: 1-201-689-8263
Conference ID: 13682790

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Liolios Group at 1-949-574-3860.

The conference call will be broadcast live and available for replay here.

A replay of the conference call will be available after 2:30 p.m. Eastern time on the same day through September 3, 2018.

Toll-free replay number: 1-844-512-2921
International replay number: 1-412-317-6671
Replay ID: 13682790

About Assure Holdings

Assure Holdings Corp. is a Colorado-based company that works with neurosurgeons and orthopedic spine surgeons to provide a turnkey suite of services that support intraoperative neuromonitoring activities during invasive surgeries. Assure employs its own staff of technologists and uses its own state-of-the-art monitoring equipment, handles 100% of intraoperative neuromonitoring scheduling and setup, and bills for all technical services provided. While Assure focuses primarily on supporting spinal and vascular surgeries, plans are in place to support other classes of medicine that rely on the standard of care that intraoperative neuromonitoring provides. For more information, visit the company’s website at

Non-IFRS Measures

Adjusted EBITDA is defined as net income/(loss) excluding interest, taxes, depreciation, share-based compensation, performance share compensation, provision for broker warrant fair value, provision for stock option fair value and deemed shares costs related to the reverse takeover merger

Forward-Looking Statements

This news release contains certain statements that may constitute forward-looking information under applicable securities laws. All statements, other than those of historical fact, which address activities, events, outcomes, results, developments, performance or achievements that Assure anticipates or expects may or will occur in the future (in whole or in part) should be considered forward-looking information. Such information may involve, but is not limited to, comments with respect to strategies, expectations, planned operations and future actions of the Company, including but not limited to the Company obtaining regulatory approval to commence trading. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or statements formed in the future tense or indicating that certain actions, events or results "may", "could", "would", "might" or "will" (or other variations of the forgoing) be taken, occur, be achieved, or come to pass. Forward-looking information is based on currently available competitive, financial and economic data and operating plans, strategies or beliefs as of the date of this news release, but involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements of Assure to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors may be based on information currently available to Assure, including information obtained from third-party industry analysts and other third-party sources, and are based on management's current expectations or beliefs regarding future growth, results of operations, future capital (including the amount, nature and sources of funding thereof) and expenditures. Any and all forward-looking information contained in this press release is expressly qualified by this cautionary statement.

Investors are cautioned that, except as disclosed in the Filing Statement any information released or received with respect to the reverse take-over may not be accurate or complete and should not be relied upon. Trading in the securities of the Corporation should be considered highly speculative.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities of the Corporation have not been and will not be registered under the United States Securities Act of 1933, as amended and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.


Cody Slach, Managing Director
Liolios Investor Relations

(in United States Dollars)
  March 31, 2018
 December 31,
Current assets    
Cash $  318,886  $  215,326  
Accounts receivable, net    20,713,887     16,624,006  
Prepaid expenses    95,940     130,060  
Due from related parties     2,082,875     2,256,117  
    Total current assets    23,211,588     19,225,509  
Equity method investments     2,857,896     2,259,663  
Equipment and furniture, net    573,867     499,123  
    Total assets $  26,643,351  $  21,984,295  
Current liabilities     
Accounts payable and accrued liabilities $  2,447,065  $  2,504,519  
Current portion of finance leases    230,969     181,787  
Income taxes payable     1,133,661     22,475  
Line of credit     500,000     -   
    Total current liabilities    4,311,695     2,708,781  
Finance leases, net of current portion     358,721     291,063  
Provision for fair value of stock options    214,415     325,515  
Provision for performance share issuance    16,011,500     16,011,500  
Provision for fair value of broker warrants    59,751     128,062  
Deferred tax liability, net     92,276     92,276  
    Total liabilities    21,048,358     19,557,197  
Capital stock    35,555     35,505  
Additional paid-in capital     6,282,129     6,079,115  
Accumulated deficit    (722,691)    (3,687,522) 
    Total shareholders' equity    5,594,993     2,427,098  
Total liabilities and shareholders' equity $  26,643,351  $  21,984,295  


(in United States Dollars)
  Three Months Ended
March 31, 2018
 Three Months Ended
March 31, 2017
    Out-of-Network fees $  5,588,841  $  2,988,506 
    Contract fees    112,310     78,065 
Total revenue    5,701,151     3,066,571 
Cost of revenues    (938,878)    (562,634)
Gross margin    4,762,273     2,503,937 
Operating expenses    
General and administrative    1,354,149     534,627 
Depreciation and amortization    86,929     45,558 
Sales and marketing    295,155     64,833 
    Total operating expenses    1,736,233     645,018 
Income from operations    3,026,040     1,858,919 
Other income/(expenses)    
Earnings from equity method investments    896,301     429,629 
Provision for broker warrant fair value    68,311     -  
Provision for stock option fair value    111,100     -  
Interest, net    (25,735)    (16,216)
    Total other income/(expenses)    1,049,977     413,413 
Income before income taxes    4,076,017     2,272,332 
Income tax expense    1,111,186     -  
Net income $  2,964,831  $  2,272,332 
Basic income per common share  $  0.08  $  0.09 
Fully diluted income per common share  $  0.07  $  0.08 


(in United States Dollars) 
 Three Months Ended
March 31, 2018
Three Months
Ended March 31,
2017 (revised)
Reported net income$  2,964,831 $  2,272,332 
Interest   25,735    16,216 
Depreciation and amortization   86,929    45,558 
Share based compensation   200,564    -  
Income tax expense   1,111,186   
Provision for broker warrant fair value   (68,311)   -  
Provision for stock option fair value   (111,100)   -  
 $  4,209,834 $  2,334,106 


(in United States Dollars) 
 March 31,
 March 31, 2017
Income attributable to common shareholders    
    Basic$  2,964,831 $  2,272,332 
    Weighted average common  share outstanding   35,515,105    24,507,862 
Basic earnings per common share$  0.08 $  0.09 
Income attributable to common shareholders    
    Basic$  2,964,831 $  2,272,332 
    Weighted average common shares outstanding   35,515,105    24,507,862 
    Dilutive effect of stock options, warrants, and performance shares   9,566,000    3,000,000 
    Weighted average common shares outstanding assuming dilution   45,081,105    27,507,862 
Fully diluted earnings per common share$  0.07 $  0.08 
Friday, August 17, 2018 - 20:30